BTRX-246040

BTRX-246040
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

BTRX-246040 is an investigational drug that acts as a selective antagonist of the nociceptin receptor (NOP receptor). It is being studied for its potential use in the treatment of various central nervous system disorders, including depression and anxiety.

Pharmacology

BTRX-246040 is a small molecule that selectively binds to the nociceptin receptor, which is a member of the opioid receptor family. Unlike traditional opioid receptors, the nociceptin receptor does not bind to classical opioids like morphine or heroin. Instead, it binds to the endogenous peptide nociceptin, also known as orphanin FQ.

The nociceptin receptor is involved in a variety of physiological processes, including the modulation of pain, mood, and stress responses. By antagonizing this receptor, BTRX-246040 may help to alleviate symptoms of depression and anxiety without the addictive potential associated with traditional opioids.

Development

BTRX-246040 was developed by BlackThorn Therapeutics, a company focused on developing treatments for neurobehavioral disorders. The drug is currently in the early stages of clinical development, with ongoing studies to evaluate its safety, tolerability, and efficacy in humans.

Mechanism of Action

The mechanism of action of BTRX-246040 involves the selective blockade of the nociceptin receptor. This blockade is thought to modulate neurotransmitter systems in the brain that are implicated in mood regulation and stress response. By inhibiting the action of nociceptin, BTRX-246040 may enhance the activity of other neurotransmitter systems, such as the serotonin and dopamine systems, which are often dysregulated in mood disorders.

Potential Applications

BTRX-246040 is being investigated for its potential use in treating a range of neuropsychiatric conditions. These include:

• Major depressive disorder
• Generalized anxiety disorder
• Post-traumatic stress disorder

The unique mechanism of action of BTRX-246040 offers a novel approach to treating these conditions, particularly for patients who do not respond to traditional antidepressants or anxiolytics.

Safety and Tolerability

Preliminary studies suggest that BTRX-246040 is well-tolerated in humans, with a safety profile that is distinct from that of traditional opioids. Common side effects observed in clinical trials include mild gastrointestinal disturbances and transient headache.

Related pages

• Nociceptin receptor
• Opioid receptor
• Depression (mood disorder)
• Anxiety disorder